When was StemlineTherapeutics founded?

StemlineTherapeutics was founded in 2003 and raised its 1st funding round 5 years after it was founded.

Where is StemlineTherapeutics located?

StemlineTherapeutics is headquartered in New York City, United States.

Who is the current CEO of StemlineTherapeutics?

Ivan Bergstein of StemlineTherapeutics. They have also founded 1 company.

How many employees does StemlineTherapeutics have?

As of Jul 31, 2026, the latest employee count at StemlineTherapeutics is 804.

Is StemlineTherapeutics a funded company?

StemlineTherapeutics is a funded company, having raised a total of $15.1M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 09, 2008.

When was the latest funding round of StemlineTherapeutics?

StemlineTherapeutics' latest funding was a $***** Series A round on Jan 17, 2012, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.79B in funding in 2026 to date.

What is the annual revenue of StemlineTherapeutics?

Annual revenue of StemlineTherapeutics is less than $1M as on Dec 31, 2017

Where does StemlineTherapeutics rank among its competitors?

StemlineTherapeutics ranks 7th amongst 96 active competitors, of which 32 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was CERo Therapeutics, which secured $750K in May, 2026.

Who are the top competitors of StemlineTherapeutics?

StemlineTherapeutics' top competitors include Ossium Health, Rigel and Ajax. Among them, CERo Therapeutics secured the most recent funding round in May, 2026.

StemlineTherapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

StemlineTherapeutics is an acquired company based in New York City (United States), founded in 2003 by Ivan Bergstein. It operates as an Oncology therapeutics innovator focused on transforming cancer patient lives. StemlineTherapeutics has raised $15.1M in funding. The company has 96 active competitors, including 32 funded and 22 that have exited. Its top competitors include companies like Ossium Health, Rigel and Ajax.

Company Details

Oncology therapeutics innovator focused on transforming cancer patient lives. The company is a biopharmaceutical organization dedicated to developing and commercializing novel, first-in-class oncology therapeutics. Their focus is on improving the lives of cancer patients by targeting difficult-to-treat cancers. They have a broad pipeline of innovative therapies in oncology. Their products include targeted therapies for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and selective estrogen receptor degraders (SERD) for estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. The company is committed to scientific leadership and innovation in the field of oncology.

Website: stemline.com/
Email ID: *****@stemline.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2003

Location

New York City, United States

Stage

Acquired

Total Funding

$15.1M in 4 rounds

Latest Funding Round

Series A, Jan 17, 2012, $*****

Investors

Avoro Capital & 2 more

Ranked

7^th among 96 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2017

Employee Count

804 as on Jul 31, 2026

Investment & Acquisitions

Primrose Therapeutics

Similar Companies

Ossium Health & 98 more

Exit Details

Acquired by Menarini (May 04, 2020)

View StemlineTherapeutics' full profile

StemlineTherapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Stemline Therapeutics Inc CIN: 1264587 , United States, Active	Aug 07, 2003	$0 - $1M (As on Dec 31, 2017)	-	-
Stemline Therapeutics, Inc. CIN: 450522567 , United States, Active		-	358 (As on Dec 31, 2024)	-

StemlineTherapeutics got acquired by Menarini on May 04, 2020 at an acquisition amount of $*****.

Click here to take a look at StemlineTherapeutics's acquisition in detail

StemlineTherapeutics has raised a total funding of $15.1M over 4 rounds. Its first funding round was on Apr 09, 2008. StemlineTherapeutics has 3 institutional investors.

Here is the list of recent funding rounds of StemlineTherapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 17, 2012	1296270	Series A	4998328	6988824	1265338	4947227
Apr 26, 2010	8628487	Series A	5714933	6673082	9296999	3808790
Mar 29, 2010	7784886	Series A	2023449	8126512	9566345	7341557

Access funding benchmarks and valuations. Sign up today!

View details of StemlineTherapeutics's funding rounds and investors

The founders of StemlineTherapeutics is Ivan Bergstein. Ivan Bergstein is the CEO of StemlineTherapeutics.

Here are the details of StemlineTherapeutics' key team members:

Ivan Bergstein: Founder & CEO of StemlineTherapeutics.
Contact Info: 1 email address

View details of StemlineTherapeutics's Founder profiles and Board Members

StemlineTherapeutics' employee count trend

StemlineTherapeutics has 804 employees as of Jul 26. Here is StemlineTherapeutics's employee count trend over the years:

Employee count trend for StemlineTherapeutics

Uncover StemlineTherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of StemlineTherapeutics include Ossium Health, Rigel and Ajax. Here is the list of Top 10 competitors of StemlineTherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	Vivo Capital, CPMG & 12 others	65/100
2nd	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MidCap Financial, ProQuest Investments & 6 others	64/100
3rd	Ajax 2019, Cambridge (United States), Acquired	Developer of targeted therapies for the treatment of hematologic malignancies	$135M	EcoR1, Goldman Sachs Asset Management & 8 others	64/100
4th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	63/100
5th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Symbiosis, Credit Mutuel Equity & 11 others	61/100
6th	Adicet Bio 2014, Menlo Park (United States), Public	Developer of immune cell therapeutic solutions for the treatment of cancer	$51M	Consensus Business Group, Samsung Venture Investment ... & 18 others	61/100
7th	StemlineTherapeutics 2003, New York City (United States), Acquired	Oncology therapeutics innovator focused on transforming cancer patient lives	$15.1M	Avoro Capital, Great Point Partners & 1 others	58/100
8th	CERo Therapeutics 2016, San Francisco (United States), Public	Developer of platforms for cellular immunotherapy	$54.8M	SRx Health, Arch Venture Partners & 1 others	58/100
9th	Charm Therapeutics 2021, London (United Kingdom), Series B	Developer of menin inhibitors designed for acute myeloid leukemia treatment	$150M	F-Prime Capital, Orbimed & 11 others	57/100
10th	Curocell 2016, Yuseong District (South Korea), Series D	Developer of immune cell therapies	$82.4M	QUAD, Atinum Investment & 21 others	56/100